Abstract: Disclosed herein are compositions and methods for cellular reprogramming. The compositions comprise one or more miRs and an activator of NF?B. Also provided are methods for enhancing or upregulating cardiomyocyte maturation in a cell or a subject and methods for inhibiting or downregulating cardiomyocyte maturation.

Abstract: Disclosed herein are compositions and methods for cellular reprogramming. The compositions comprise one or more miRs and an activator of NF?B. Also provided are methods for enhancing or upregulating cardiomyocyte maturation in a cell or a subject and methods for inhibiting or downregulating cardiomyocyte maturation.

Abstract: The present disclosure provides compositions and methods for the reprogramming of cells such as fibroblasts into cardiomyocytes. The invention provided herein features a chemically defined media and methods of reprogramming cells to increase cardiac gene and protein expression in cardiac fibroblasts and other fibroblasts, e.g. dermal fibroblasts. The media and methods also enhance miR-combo mediated cardiac reprogramming of fibroblasts to cardiomyocytes. Thus, the invention encompasses a chemically defined reprogramming media comprising a base tissue culture media, insulin-transferrin-selenium (ITS) or ascorbic acid in a somatic cell-reprogramming, e.g., fibroblast-to-cardiomyocyte-reprogramming, amount.

Abstract: The present disclosure provides compositions and methods for the reprogramming of cells such as fibroblasts into cardiomyocytes. The invention provided herein features a chemically defined media and methods of reprogramming cells to increase cardiac gene and protein expression in cardiac fibroblasts and other fibroblasts, e.g. dermal fibroblasts. The media and methods also enhance miR-combo mediated cardiac reprogramming of fibroblasts to cardiomyocytes. Thus, the invention encompasses a chemically defined reprogramming media comprising a base tissue culture media, insulin-transferrin-selenium (ITS) or ascorbic acid in a somatic cell-reprogramming, e.g., fibroblast-to-cardiomyocyte-reprogramming, amount.

Abstract: A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic conditions.

Abstract: A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic condtions.

Abstract: A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic condtions.

Abstract: The invention feature methods and compositions for treating ischemic and reperfusuin related injury such as cardiac disorders.

Abstract: A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic condtions.

Abstract: A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic conditions.

Abstract: A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic condtions.

Abstract: The invention provides compositions such modified cells and methods of promoting healing of an injured tissue by enhancing the migration of primary or immortalized progenitor or stem cells and enhancing their engraftment into a target tissue site in mammalian recipient such as a human subject. For example, the cells are adult bone marrow derived cells, such as mesenchymal stem cells (MSC) or hematopoetic stem cells such a endothelial progenitor cells (EPCs) and the target tissue is an injured and/or ischemic heart.

Abstract: The invention feature methods and compositions for treating ischemic aand reperfusuin related injury such as cardiac disorders.

Abstract: A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic conditions.

Abstract: Compositions and methods for cellular and tissue protection, repair, and regeneration are described. Mesenchymal cell-derived paracrine factors confer a therapeutic benefit to a variety of injured, compromised or diseased tissues such as myocardial tissue.

Abstract: Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host.

Abstract: The invention feature methods and compositions for treating ischemic aand reperfusuin related injury such as cardiac disorders.

Abstract: A method of enhancing injury-induced revascularization of a tissue as treatment of a disease, such as coronary artery disease, is described. The method involves (i) creating injury in a tissue (e.g., muscle, such as cardiac muscle) by, for example, use of a laser, an ultrasonic device, or a Thermal probe, and (ii) injecting into the tissue a revascularization-promoting molecule or a nucleic acid molecule encoding a revascularization-promoting molecules Also described is an apparatus that can be used to practice this method.

Abstract: An angiotensin II type 2 receptor (AT.sub.2 receptor), structurally related cell receptors, nucleic acids encoding such AT.sub.2 receptors, AT.sub.2 receptor-related peptides, and methods of using AT.sub.2 receptors and AT.sub.2 receptor-encoding nucleic acids are provide. AT.sub.2 receptor-specific binding compounds are disclosed including antibodies to AT.sub.2 receptor epitopes. The invention provides AT.sub.2 receptor-based pharmaceutical compositions and AT.sub.2 receptor-based methods rot screening chemical libraries for regulators of cell growth/differentiation. In particular, the invention provides methods for identifying agonists and antagonists of the disclosed AT.sub.2 receptor. Such compositions find broad utility in the treatment of cardiovascular disease, cancer, reproductive disease, etc.